Shareholder

Shareholder structure as of 27.11.2017.
The table below presents the shareholder structure with a special list of shareholders having at least 5% of share of votes on the General Meeting of the Company (in accordance with shareholders’ notifications from Art. 69 on Public Offering and ESPI reports on shareholders with at least 5% of total votes on the Issuer’s General Meetings).

ShareholderNumber of shares
(% in KZ)
Number of votes
(% in WZ)
Waldemar Sierocki4 790 504
(7,69%)
9 325 588
(11,40%)
Przemysław Sierocki4 785 083
(7,69%)
9 320 166
(11,39%)
Organizacja polskich
dystrybutorów farmaceutycznych
6 273 005
(10,08%)
6 273 005
(7,67%)
Wiktor Napióra5 023 005
(8,07%)
9 796 010
(11,97%)
Dariusz Kucowicz6 523 005
(10,48%)
11 296 010
(13,81%)
w tym pośrednio poprzez Medicare Sp.  z o.o.4 773 005
(7,67%)
9 546 010
(11,67%)
Value Fundusz Inwestycyjny Zamknięty4 236 261
(6,80%)
4 236 261
(5,18%)
Pozostali <5%30 629 547
(49,20%)
31 561 350
(38,58%)
RazemRazemRazem
* pośrednio poprzez Medicare Sp. z o.o. posiadającą 4 773 005 akcji (7,67% w KZ) dających prawo do 9 546 010 głosów na WZ (11,67%) )

Investor’s calendar

Transferring periodical reports in 2017 shall be on the following dates:

REPORTDATE OF PUBLICATION
annual report for the financial year 201724 April 2018

Investor’s calendar

Transferring periodical reports in 2017 shall be on the following dates:

REPORT                                                                 DATE OF PUBLICATION

annual report for the financial year 2017 . . . . . . . . . . . . . . . . 24 April 2018

quarterly report for the 1st quarter of 2018   . . . . . . . . . . . .  23 May 2018

semi-annual report for the 1st half of 2018 . . . . . . . . . . . . . . . 25 September 2018

quarterly report for the 3rd quarter of 2018  . . . . . . . . . . . . . . . 28 November 2018

According to § 101 sec. 2 of the Decree of the Minister of Finance dated 19 February 2009 on current and periodic information provided by issuers of securities and conditions for recognising as equivalent the information required by the law of a non-member state (Dz. U. [Journal of Laws] 2014 no. 0 item 133) the Company shall not publish the quarterly report for the 4th quarter of 2017 and for the 2nd quarter of 2018.

Information concerning closed periods

Regulation (EU) no. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC (MAR Regulation) introduces the concept of so called closed periods.

According to art. 19 sec. 11 a person discharging managerial responsibilities in a Company (i.e. Members of Supervisory Board and Management Board) cannot make any transactions on own account or on behalf of a third party, directly or indirectly, concerning shares or debt financial instruments of an issuer or derivative instruments or other financial instruments concerning them, for the closed period of 30 calendar days before publishing of a periodical report.

Pursuant to art. 19 sec. 12 of the MAR Regulation in the circumstances referred to in the regulation, the Company may allow the person discharging managerial responsibilities to make transactions on own account or on behalf of third party during the closed period.

Furthermore, according to the MAR Regulation, persons having access to confidential information, before it is published, shall be prohibited especially from:

use of confidential information,

disclosing confidential information to unauthorised persons and entities,

giving recommendations or inducing to acquire or dispose of financial instruments,

make transactions involving securities issued by the Company and derivative instruments, attempt to engage in such trading as well as modify or cancel the orders after acquiring confidential information.

 

Contact information for the investors

For all cases concerning Investor Relations please contact:

 

Chief Financial Officer

Włodzimierz Parzydło

tel.: +48 81 533 82 21 ext. 211

e-mail.: wlodzimierz.parzydlo@biomed.lublin.pl

 

Address:

“BIOMED-LUBLIN” Wytwórnia Surowic i Szczepionek Spółka Akcyjna

20-029 Lublin ul. Uniwersytecka 10